EURO COSMETICS Magazine • Givaudan completes the acquisition of major cosmetic ingredients portfolio from Amyris • admin • admin

Givaudan completes the acquisition of major cosmetic ingredients portfolio from Amyris

Strengthening our leadership in biotechnology for cosmetic ingredients for a sustainable future

Givaudan, the global leader in Fragrance & Beauty, today announces that it has completed the acquisition of a major cosmetic ingredients portfolio from Amyris, Inc (Nasdaq: AMRS). Givaudan had announced that it had reached an agreement for this transaction in February 2023.

Amyris is a leading biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform in beauty, health & wellness and flavours & fragrances markets. Amyris and Givaudan have a strong partnership to leverage the value of Amyris’ technology platform for designing, scaling and manufacturing the best performing bio-fermented ingredients.

Maurizio Volpi, President Givaudan Fragrance & Beauty said: “It is an important step for Givaudan as we will reinforce our leadership in biotech, while continuing to offer efficient and sustainable solutions for the beauty industry, thanks to our longstanding partnership with Amyris. The complementary nature of both capabilities will further enhance our ability to support our customers with breakthrough innovations.”

“We are very pleased with the expansion of our long term partnership with Givaudan. Our unique biomanufactured molecules enable significant expansion to the Givaudan Active Beauty business leadership in the supply of clean, sustainable ingredients. We expect the reach and scale of Givaudan to accelerate our sales growth and to support the beauty industry’s transition to sustainably produced chemistry,” said John Melo, Amyris President and Chief Executive Officer.

Markus Rassmann, Head of Active Beauty, said: “We are delighted to enrich our market-leading biotech cosmetic ingredients portfolio with the Amyris products. With this acquisition we enhance our unique biotech palette, leading the market towards a more sustainable future.”

While terms of the deal have not been disclosed, Amyris’ cosmetic business would have represented approximately USD 30 million of incremental sales to Givaudan’s results in 2022 on a proforma basis. Givaudan funded the transaction from existing resources.

About Givaudan
Givaudan is a global leader in Fragrance & Beauty and Taste & Wellbeing. We celebrate the beauty of human experience by creating for happier, healthier lives with love for nature. Together with our customers we deliver food experiences, craft inspired fragrances, and develop beauty and wellbeing solutions that make people look and feel good. In 2022, Givaudan employed almost 16,700 people worldwide and achieved CHF 7.1 billion in sales with a free cash flow of 6.7%. With a heritage that stretches back over 250 years, we are committed to driving long-term, purpose-led growth by improving people’s health and happiness and increasing our positive impact on nature. This is Givaudan. Human by nature. Discover more at www.givaudan.com.

About Givaudan Fragrance & Beauty
Givaudan Fragrance & Beauty craft inspired fragrances to perfume lives and memories, and develop innovative beauty and wellbeing solutions that make people look and feel good all over the world. Nature is both our responsibility and our most precious muse. We are just as committed to sustainability as we are to creating innovative products that satisfy consumer needs and anticipate their desires. With a collaborative approach that favours co-creation, we have built a diverse portfolio across personal care, fabric care, hygiene, home care, fine fragrances, and beauty, reflecting our multidisciplinary expertise. This is Givaudan. Human by nature. Learn more at www.givaudan.com/fragrance-beauty.

About Amyris
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the clean health & beauty and flavours & fragrances markets to sustainable ingredients through fermentation and the company’s proprietary Lab-to-Market™ technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world’s top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit www.amyris.com.

Forward-looking statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as Amyris’ expectations regarding the closing of the transaction with Givaudan and the financial benefits and timing thereof. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris’ liquidity and ability to fund operating and capital expenses, risks related to its financing activities, risks related to potential delays or failures in completing and integrating planned acquisitions, risks related to potential delays or failures in development, regulatory approval, launch, production and commercialisation of products, risks related to global inflation and policy measures undertaken to address inflation, the COVID-19 pandemic and any other geopolitical events, including Russia’s invasion of Ukraine, resulting in global economic, financial and supply chain disruptions that may negatively impact Amyris’ business operations and financial results or cause market volatility, risks related to Amyris’ reliance on third parties particularly in the supply chain, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

For further information please contact
Pierre Bénaich, Givaudan Media and Investor Relations
T +41 22 780 9053
E pierre.benaich@givaudan.com


Pauline Martin, Fragrance & Beauty Communications
E pauline.martin.pm1@givaudan.com

admin

Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.

You don't want to miss important information from the personal care industry and much more?

Subscribe to our monthly newsletter for free to stay up to date!

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter and stay tuned.

Wir verwenden Brevo als unsere Marketing-Plattform. Wenn Sie das Formular ausfüllen und absenden, bestätigen Sie, dass die von Ihnen angegebenen Informationen an Brevo zur Bearbeitung gemäß den Nutzungsbedingungen übertragen werden

Cookie Consent with Real Cookie Banner